logo
ScreenersREIT EarningsREIT SectorsMarketplaceLearn
Logo

Harmony Biosciences Holdings, Inc.

HRMY

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmonyā€¦ read more

Healthcare

Biotechnology

3 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$36.87

Price

+0.99%

$0.36

$36.51

Previous Close

$36.48

Open

Premium

52w Discount
Market Cap

$2.121b

Mid

Price/Earnings

11.9x

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$772.527m

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

$180.904m

-

1y CAGR

-

3y CAGR

-

5y CAGR
EPS

$3.10

-

1y CAGR

-

3y CAGR

-

5y CAGR
Book Value

$773.080m

$1.108b

Assets

$334.928m

Liabilities

$172.095m

Debt
Debt to Assets

15.5%

0.6x

Debt to EBITDA
Free Cash Flow

$258.729m

-

1y CAGR

-

3y CAGR

-

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
ā†‘ TopSummaryPriceFinancialsPress Releases
logo
About usFAQ
All the information presented is collected from official and public documents such as: Quarterly and Annual Reports, 10-K (US), Information Form (Canada), Presentations and the Investor Relations (IR) section of the company's website.
The data displayed by alreits.com is solely for informational purposes, we do not recommend the buying, holding or selling of any of the stocks on the website. If you have no experience in the stock market, please talk to your personal licensed investment advisor before making any decisions.